New pill shows promise for Long-Term arthritis control

NCT ID NCT04049448

First seen Nov 17, 2025 · Last updated May 08, 2026 · Updated 24 times

Summary

This study looked at the long-term safety of a drug called ABX464 in 40 adults with moderate to severe rheumatoid arthritis. All participants had already completed a 12-week treatment course. The goal was to see if taking the drug for up to 52 more weeks was safe and helped keep the disease under control. This is not a cure, but a way to manage symptoms and slow disease activity.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHR d'Orléans

    Orléans, France

  • CHU DE MONTPELLIER - Hôpital Lapeyronie

    Montpellier, France

  • CHU de Brest - Hôpital Cavale Blanche

    Brest, France

  • CMed Rehabilitációs és Diagnosztikai Központ

    Székesfehérvár, Hungary

  • CRU Hungary Ltd.

    Miskolc, Hungary

  • ClinicMed Daniluk, Nowak Sp. J.

    Bialystok, Poland

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Complex Medical Centre - Déli Klinika

    Budapest, Hungary

  • Medyczne Centrum Hetmańska

    Poznan, Poland

  • NZOZ Lecznica MAK-MED S.C.

    Nadarzyn, Poland

  • National Institute of Geriatrics

    Warsaw, Poland

  • Pratia MCM

    Krakow, Poland

  • UZ Gent

    Ghent, Belgium

  • Zespół Poradni Specjalistycznych REUMED

    Lublin, Poland

Conditions

Explore the condition pages connected to this study.